SIMRIS GROUP
INTERIM REPORT
JANUARY–SEPTEMBER 2026

QUARTER 3, JULY – SEPTEMBER 2026

- Net revenue decreased by 51% to SEK 236k (484k).
- EBITDA decreased by 16% to SEK -4 229k (-3 639k).
- EBIT/Operating result decreased by 8% to SEK –7 727k (–7 152k).

INTERIM PERIOD, JANUARY – SEPTEMBER 2026

- Net revenue decreased by 36% to SEK 856k (1 330k).
- EBITDA improved by 19% to SEK -8 339k (-10 343k).
- EBIT/Operating result improved by 11% to SEK –18 790k (–21 133k).

KEY EVENTS DURING THE QUARTER

- Holders of warrants have exercised 223,3 million warrants amounting to total proceeds of EUR 1 015k.
- Antibody-drug conjugate (ADC) expert Professor Andreas Pahl has been appointed Chief Executive Officer for the subsidiary Simris Biologics GmbH.
- Biotechnology expert Dr. Tiffany J. Vora has been appointed as a strategic advisor.
- Simris Group confirms its strategy to develop amanitin-derived novel payloads to overcome treatment resistance in both liquid and solid tumors.

KEY EVENTS AFTER THE END OF THE QUARTER

- Entered into a new Memorandum of Understanding with Immunrise Biocontrol France SAS regarding the lease and subsequent acquisition of the Company's industrial site and related assets in Hammenhög.
- Appointment of Dr. András Strassz as Chief Medical Officer (CMO).

THE PERIOD IN BRIEF – GROUP

SEK thousands	Jul-Sep 2026	Jul-Sep 2025	Δ	Jan-Sep 2026	Jan-Sep 2025	Δ	Full year 2025
Net revenue	236	484	*-51%*	856	1 330	*-36%*	1 615
EBITDA	-4 229	-3 639	*-16%*	-8 339	-10 343	*19%*	-15 539
EBIT / Operating result	-7 727	-7 152	*-8%*	-18 790	-21 133	*11%*	-29 562
Result before tax	-9 469	-7 085	*-34%*	-23 193	-22 058	*-5%*	-30 003
Cash flow from operating activities	-3 598	-4 541	*21%*	-10 119	-11 726	*14%*	-16 045
Cash at the end of the period	10 428	3 798	*175%*	10 428	3 798	*175%*	1 465

CEO UPDATE

Simris Group Interim CEO update

The third quarter marked an important milestone in the transformation of Simris Group into a focused oncology biotechnology company. Following a thorough strategic review, we confirmed our decision to advance two amanitin-based antibody-drug conjugate (ADC) programs towards clinical development. This represents a significant step in establishing a clear direction for the Group and focusing our resources on areas where we believe we can create the greatest long-term value.

Under the leadership of Professor Andreas Pahl, CEO of Simris Biologics, we have continued to strengthen our development capabilities and build the organisation required to execute this strategy. Following the end of the quarter, we also announced the appointment of Dr. András Strassz as Chief Medical Officer, adding valuable clinical development expertise to the team.

I would also like to thank our shareholders for their continued support. The exercise of 223.3 million warrants, representing gross proceeds of approximately EUR 1 million, has provided additional funding to support our strategic priorities. The transaction was fully paid and registered in October 2026.

We have also made further progress in the planned divestment of our Hammenhög facility. In October, we entered into a new Memorandum of Understanding with Immunrise Biocontrol France SAS, establishing commercial terms for the lease and subsequent acquisition of the facility. While completion remains subject to financing and definitive agreements, this represents an important step towards reducing our operational commitments to the facility and allowing us to concentrate our resources on Simris Biologics.

Looking ahead, our priorities remain clear: advancing our ADC development programs, maintaining financial discipline and completing the transition towards a focused biotechnology business. While the financing environment remains challenging, I believe the progress made during the quarter has significantly strengthened the position of Simris in the fast growing ADC Payload market.

Daniel Kubitza
Interim CEO Simris Group

Simris Biologics CEO update

The third quarter marked an important step in building Simris Biologics into a fully fledged ADC company. In line with our strategy, after quarter-end we appointed a Chief Medical Officer, bringing clinical development expertise into the leadership team as we prepare to move our programmes towards the clinic. With this appointment, our core team is now complete, giving us the scientific, clinical and operational capabilities needed to execute our plans.

In October, Simris mutually agreed with Lonza to void the previously announced 2023 contract granting Lonza the exclusive right to offer our technology to new and existing customers seeking novel payloads to develop into ADC medicines. This decision was taken by Simris in order to expand our flexibility in choosing partners as we continue to expand our technology platform.

The preclinical studies advancing the microcystin platform at our CRO partner are going ahead as planned. The next step is to begin a new round of optimization that will be verified with in-vitro and in vivo studies.

We also made good progress in ADC design. We advanced work on combining our payloads with antibodies and linkers to generate ADCs that can be developed clinically. In parallel, we continued to evaluate complementary non-cyanobacterial payloads to broaden our options and accelerate our path to the clinic.

ADCs remain one of the fastest-growing areas in oncology, and the need for novel payloads with new mechanisms of action is becoming increasingly clear as resistance and toxicity limit current approaches. I believe Simris is well positioned to address this need.

The financing environment for biotechnology companies remains challenging, and we will continue to manage our resources with discipline. With a complete team and a clear strategic direction, I look forward to reporting further progress in the coming quarters.

Andreas Pahl
CEO Simris Biologics

OVERVIEW

NET REVENUE AND PROFIT

The sales for the quarter decreased by 51% and amounted to SEK 236k (484k) and the sales for the interim period decreased by 36% and amounted to SEK 856k (1 330k).

The EBITDA result for the quarter decreased by 16% to SEK -4 229k (-3 639k) and the EBITDA result for the interim period improved by 19% to SEK -8 339k (-10 343k). The EBIT/ Operating result for the quarter decreased by 8% to SEK –7 727k (–7 152k) and the EBIT/ Operating result for the interim period improved by 11% to SEK –18 790k (–21 133k).

The financial net for the quarter amounted to SEK -1 742k (67k) and the financial net for the interim period amounted to SEK -4 403k (-925k). As of 1 January 2026, exchange rate differences attributable to the EUR-denominated earn-out liability related to the acquisition of Simris Biologics are recognized in the Group's financial income and expenses. In the Parent Company, such exchange rate adjustments continue to be capitalized as part of the acquisition value of the shares. For the quarter, exchange rate adjustments related to the earn-out liability concerning Simris Biologics amounted to SEK -1 894k (0) and for the interim period SEK -4 090k (0).

The total inventory value amounted to SEK 1 128k (490k) at the end of the interim period. All inventory accounted for at the end of the interim period is related to Simris Biologics.

FIXED ASSETS

The total book value of the Group's fixed assets amounted to SEK 129 190k (137 978k) at the end of the period. Intangible Assets at the period were SEK 118 152k (125 851k). Tangible Assets at the end of the period were SEK 11 038k (12 127k).

The depreciation of fixed assets was made according to relevant accounting standards with SEK 3 498k (3 513k) during the quarter and with SEK 10 451k (10 790k) during the interim period. Fixed assets are depreciated over 5–10 years for most fixtures and fittings, and over the remaining lifetime for patents (15 years for the patents and technology gained through the Cyano Biotech acquisition, now renamed to Simris Biologics), and up to 50 years for the buildings.

LIQUIDITY AND FINANCING

Cash flow from operating activities improved by 21 percent to SEK -3 598k (-4 541k) during the quarter and cash flow from operating activities improved by 14 percent to SEK -10 119k (-11 726k) during the interim period. Cash flow amounted to SEK 2 441k (2 772k) for the quarter and cash flow amounted to SEK 8 963k (1 852k) for the interim period. At the end of the period, cash and cash equivalents amounted to SEK 10 428k (3 798k). The total liabilities at the end of the period amounted to SEK 141 017k (157 171k).

The deferred tax liability at the end of the quarter amounting to SEK 35 445k (37 761k) is not a payable debt as it is related to the purchase price allocation of Simris Biologics.

It is important to note that €8m of the long-term debt on the balance sheet is associated with the acquisition of Cyano Biotech (now Simris Biologics). This is the maximum earn-out remaining to be paid for the acquisition of the ADC platform. For this to become payable, Simris Biologics would have to first earn sales revenue of at least €80m from the ADC platform over the next 15 years. This revenue would be expected to be at a very high profit margin. Importantly, Simris Group has executed a back-to-back agreement with Simris Biologics whereby Simris Biologics will recompense Simris Group for the amount of this future earn-out payment.

On December 23, 2024, Simris entered into convertible loan agreements totaling EUR 600k, with an option for the lender to increase the amount by an additional EUR 900k. In addition, at the extraordinary general meeting held on January 20, 2025, the Company resolved to enter into convertible loan

agreements totaling EUR 140k with related parties and members of management. The loans were provided by Frank Puccio (EUR 50k), Royce CoLabs AB, a company controlled by Jonathan Royce (EUR 10k), Magnus Högström (EUR 30k), Arminnovate Ltd, a company controlled by Dr. Alexis Roberts-McIntosh (EUR 20k), and Christoffer Tell AB, a company controlled by Christoffer Tell (EUR 30k). The loans initially carried interest at 1.0 percent per month and matured on December 31, 2025. At the annual general meeting held on May 28, 2025, the maturity date was extended to March 31, 2026. From August 1, 2025, no further interest accrued on the loans. The lenders had the right to convert outstanding loan amounts, including accrued interest, into newly issued class B shares at a subscription price of SEK 0.05 per share, subject to adjustment in future capital raisings. Following the resolutions at the extraordinary general meeting held on January 19, 2026, outstanding loan amounts and accrued interest under the EUR 600k facility were set off through a directed issue of 140 905 267 units, each consisting of one (1) class B share and two (2) warrants, corresponding to 140 905 267 new class B shares and 281 810 534 warrants. The share capital increased by SEK 1 409 052.67 as a result of the issuance of the class B shares and may increase by an additional SEK 2 818 105.34 upon full exercise of the warrants. At the same extraordinary general meeting, outstanding loan amounts and accrued interest relating to the EUR 140k management and related-party loans were converted into newly issued class B shares at a subscription price of SEK 0.05 per share. The conversion was allocated as follows: Frank Puccio 11 654 346 shares, Royce CoLabs AB 2 330 123 shares, Magnus Högström 7 006 032 shares, and Christoffer Tell AB 6 992 607 shares. In addition, CEO Daniel Kubitza invested EUR 40k in cash and received 8 800 000 newly issued class B shares.

The Brand Laboratories FZ (TBL) had previously provided the business with a loan facility of €778k. The facility maturity date is 1 January 2027, and interest was charged at 1.0% per month until 31 July 2025. The total loan including accumulated interest amounted to €856k as of 31 July 2025. After August 1, 2025 Interest is charged at 0% per month.

On 16 December 2025, the Board of Directors, by virtue of the authorization granted by the annual general meeting held on 28 May 2025, resolved on a directed issue of 330 000 000 units, each unit consisting of one (1) class B share and two (2) warrants of series 2025/2027, at a subscription price of SEK 0.05 per unit. The warrants were issued free of charge. Through the issue, the Company received proceeds of approximately EUR 1,5 million before transaction costs. The issue resulted in the issuance of 330 000 000 new class B shares, increasing the share capital by SEK 3 300 000, from SEK 6 251 448,98 to SEK 9 551 448,98. Each warrant entitles the holder to subscribe for one (1) new class B share at SEK 0.05 during the period up to and including 31 December 2027. Upon full exercise of all warrants, an additional 660,000,000 class B shares may be issued, corresponding to a further increase in share capital of SEK 6,600,000. The transaction was subscribed to in December 2025 and January 2026. The transaction is fully paid for and registered in January 2026.

During the third quarter, the Company recognized the exercise of 223.3 million warrants, corresponding to gross proceeds of approximately EUR 1 015k. As of 30 September 2026, EUR 430k of the subscription proceeds remained outstanding and was recognized as receivable. The full transaction was recognized in equity as of the reporting date. Subsequent to the end of the reporting period, the outstanding amount was received in full, and the resulting share issue was registered with the Swedish Companies Registration Office in October 2026.

The Board of Directors wishes to inform stakeholders that the company's current cash reserves may not be sufficient to cover ongoing operations through the end of the calendar year. We recognize the gravity of this situation and are actively working on multiple fronts to secure the necessary funding to support the company’s ongoing operations and future growth. Efforts are underway and the Board is exploring various financing options, including debt refinancing, potential loans, new investment opportunities, and strategic partnerships. The Board remains committed to ensuring the long-term stability and success of the company and will continue to update stakeholders as progress is made.

EQUITY

The Group's equity amounted to SEK 5 177k (-14 259k) at the end of the quarter. The solidity was 3,5 percent, compared with -0,3 percent on December 31, 2025.

As of 30 September 2026, the total number of Class B shares amounted to 1 349 793 273, with a registered share capital of SEK 13 497 932,73. Subsequent to the reporting period, the exercise of warrants was registered with the Swedish Companies Registration Office in October 2026, increasing the total number of Class B shares to 1 573 093 273 and the registered share capital to SEK 15 730 932,73. The quota value remains unchanged at SEK 0.01 per share.

OPTION PROGRAM

At the end of the quarter Simris Group had options from two outstanding option programs from capital raise of units.

Series 2025/2027 consists of 448 800 000 options and was issued to the investors in January 2026. Each option gives the right to subscribe for one Class B share at a subscription price of SEK 0.05 per share until the end of 2027. Full exercise of the outstanding options would result in a dilution of approximately 22,2 percent, based on the number of registered shares as of October 2026, including the new shares issued on exercise.

Series 2026/2027 consists of 269 710 534 options and was issued to the investors in January 2026. Each option gives the right to subscribe for one Class B share at a subscription price of SEK 0.05 per share until the end of 2027. Full exercise of the outstanding options would result in a dilution of approximately 14,6 percent, based on the number of registered shares as of October 2026, including the new shares issued on exercise.

STAFF AND ORGANIZATION

The average number of full-time equivalents (FTEs) employed during the quarter amounted to 6 (6) and the average number of full-time equivalents (FTEs) employed during the interim period amounted to 5 (6). At the end of the quarter, the Group had 7 FTEs excluding the CEO and the CFO who are contracted as consultants.

PARENT COMPANY

Simris Group AB is the parent company. Net revenue for the Parent Company during the quarter amounted to SEK 0k (0k) and amounted to SEK 0k (0k) for the interim period. EBIT/ Operating result amounted to SEK -2 224k (-2 920k) for the quarter and amounted to SEK -6 593k (-7 949k) for the interim period. Result before tax amounted to SEK -3 828k (-3 014k) for the quarter and amounted to SEK -11 426k (-8 831k) for the interim period.

TRANSACTIONS WITH RELATED PARTIES

At the extraordinary general meeting held on January 20, 2025, Simris Group AB (publ) resolved to enter into loan agreements totaling EUR 140 000 with related parties, including Frank Puccio (EUR 50 000), Royce CoLabs AB, a company controlled by Jonathan Royce (EUR 10 000), Magnus Högström (EUR 30 000), Arminnovate Ltd, a company controlled by Dr. Alexis Roberts-McIntosh (EUR 20 000), and Christoffer Tell AB, a company controlled by Christoffer Tell (EUR 30 000). Due to conflicts of interest among board members, the agreements were submitted to the general meeting for approval in accordance with the Swedish Companies Act. The loans carried an interest rate of 1.0 percent per month and mature on December 31, 2025. The lenders had the right to convert the outstanding loan amounts, including accrued interest, into B-shares at a subscription price of SEK 0.05 per share, subject to adjustment in the event of a future capital raise. At the annual general meeting held on May 28, 2025, Simris Group AB (publ) resolved to extend the maturity date to March 31, 2026. From 1 August 2025 the interest rate of the loan is 0.0 percent per month. At the extraordinary general meeting held on 19 January 2026, it was resolved that the outstanding loan amounts be set off against newly issued class B shares at

a subscription price of SEK 0,05 per share, Frank Puccio 11 654 346 shares, Royce CoLabs AB 2 330 123 shares, Magnus Högström 7 006 032 shares and Christoffer Tell AB 6 992 607 shares.

In addition to normal Board work during the quarter, Board Directors performed consulting services for the company, of which Magnus Högström received SEK 30k, Jonathan Royce SEK 29k and Julian Read SEK 80k.

ACCOUNTING PRINCIPLES

Simris Group prepares its accounts in accordance with the Annual Accounts Act and the Accounting Board's general advice 2012:1(K3). Information on accounting principles in general is provided in the Annual Report for 2025.

AUDIT

This report has not been reviewed by Simris Group's auditor.

RISKS AND UNCERTAINTIES

Simris Group's operations, financial position and earnings can be affected by a number of risks and uncertainties. These are described in Simris Group's Annual Report for 2025, at www.simrisgroup.com.

Simris Group is in the start-up phase and still lacks sufficient earnings to cover the costs of the business through sales revenue. Simris Group is reliant upon planned additional external funding to be able to continue its operations, repay loans, and implement growth plans. Whilst the Board is confident that the business is in its strongest position ever, and that it will be able to raise the funds required for future investment and growth, there is always a risk that capital markets change and that new capital cannot be accessed when needed, or that new capital cannot be obtained on satisfactory terms, or that the procured capital is insufficient to finance the planned operations in accordance with forecasts and objectives.

11 November 2026

The Board of Directors and the CEO confirm that this report provides a fair overview of the Group's operations, position and results.

Daniel Kubitza
Interim CEO

Jonathan Royce
Chairman

Magnus Högström
Board Director

Frank Puccio
Board Director

Richard Todd
Board Director

Hadrien Forterre
Board Director

Julian Read
Board Director

INCOME STATEMENT - CONSOLIDATED GROUP

SEK thousands	Jul-Sep 2026	Jul-Sep 2025	Jan-Sep 2026	Jan-Sep 2025	Full year 2025
Net revenue	236	484	856	1 330	1 615
Change of finished goods and work in progress	0	0	0	0	610
Other operating income	418	1 488	2 643	1 516	1 780
Raw materials and consumables	-212	-128	-572	-293	-460
Other external expenses	-2 290	-3 891	-5 848	-8 630	-13 259
Personnel expenses	-2 381	-1 592	-5 418	-4 266	-5 825
Depreciation and amortization	-3 498	-3 513	-10 451	-10 790	-14 023
Operating result / EBIT	**-7 727**	**-7 152**	**-18 790**	**-21 133**	**-29 562**
Financial net	-1 742	67	-4 403	-925	-441
Result before tax	**-9 469**	**-7 085**	**-23 193**	**-22 058**	**-30 003**
Tax	844	808	2 435	2 471	3 192
Result for the period	**-8 625**	**-6 277**	**-20 758**	**-19 587**	**-26 811**
(Attributable to the parent company's shareholders)	**-8 625**	**-6 277**	**-20 758**	**-19 587**	**-26 811**

BALANCE SHEET - CONSOLIDATED GROUP

SEK thousands	30 Sep 2026	30 Sep 2025	31 Dec 2025
Assets			
Fixed Assets			
Intangible assets	118 152	125 851	120 553
Tangible assets	11 038	12 127	11 355
Total Fixed Assets	**129 190**	**137 978**	**131 908**
Current Assets			
Inventory	1 128	490	1 077
Other receivables	5 448	646	13 931
Cash and bank balances	10 428	3 798	1 465
Total Current Assets	**17 004**	**4 934**	**16 473**
Total Assets	**146 194**	**142 912**	**148 381**
Equity and Liabilities			
Equity	5 177	-14 259	-470
Provisions			
Deferred tax	35 445	37 761	36 170
Liabilities			
Long-term Liabilities	91 519	89 932	87 680
Short-term Liabilities	14 053	29 478	25 001
Total Liabilities	**141 017**	**157 171**	**148 851**
Total Equity and Liabilities	**146 194**	**142 912**	**148 381**

CASH FLOW ANALYSIS - CONSOLIDATED GROUP

SEK thousands	Jul-Sep 2026	Jul-Sep 2025	Jan-Sep 2026	Jan-Sep 2025	Full year 2025
Cash flow from operating activities before changes in working capital	-4 140	-3 708	-8 623	-11 310	-15 933
Cash flow from working capital	542	-833	-1 496	-416	-112
Cash flow from operating activities	**-3 598**	**-4 541**	**-10 119**	**-11 726**	**-16 045**
Cash flow from investing activities	-1 848	0	-2 176	0	-224
Cash flow from financing activities	7 887	7 313	21 258	13 578	15 788
Cash flow for the period	**2 441**	**2 772**	**8 963**	**1 852**	**-481**
Cash and cash equivalents opening balance	7 987	1 026	1 465	1 946	1 946
Cash and cash equivalents closing balance	**10 428**	**3 798**	**10 428**	**3 798**	**1 465**

CHANGES IN EQUITY - CONSOLIDATED GROUP

SEK thousands	Jul-Sep 2026	Jul-Sep 2025	Jan-Sep 2026	Jan-Sep 2025	Full year 2025
Opening balance	767	-7 745	-470	5 641	5 641
Issue	11 165	0	23 074	0	21 069
Issue costs	0	0	-803	0	0
Translation differences	1 870	-237	4 134	-313	-369
Result for the period	-8 625	-6 277	-20 758	-19 587	-26 811
Closing balance	**5 177**	**-14 259**	**5 177**	**-14 259**	**-470**

KEY FIGURES - CONSOLIDATED GROUP

	Jul-Sep 2026	Jul-Sep 2025	Jan-Sep 2026	Jan-Sep 2025	Full year 2025
Net revenue (kSEK)	236	484	856	1 330	1 615
EBIT (kSEK)	-7 727	-7 152	-18 790	-21 133	-29 562
Cash at the end of the period (kSEK)	10 428	3 798	10 428	3 798	1 465
Equity (kSEK)	5 177	-14 259	5 177	-14 259	-470
Earnings per share (SEK)	neg.	neg.	neg.	neg.	neg.
Earnings per share after full dilution (SEK)	neg.	neg.	neg.	neg.	neg.
Equity per share (SEK)	0,004	-0,02	0,004	-0,02	-0,001
Equity per share after full dilution(SEK)	0,002	-0,02	0,002	-0,02	-0,001
Number of shares, average	1 349 793 273	625 144 898	1 285 615 974	555 434 779	574 194 370
Number of shares, end of period	1 349 793 273	625 144 898	1 349 793 273	625 144 898	842 104 898
Number of shares after full dilution*	2 291 603 807	625 144 898	2 291 603 807	625 144 898	842 104 898
Solidity (%)	3,5	-10,0	3,5	-10,0	-0,3
Balance sheet total (kSEK)	146 194	142 912	146 194	142 912	148 381
Cash liquidity (%)	113	15	113	15	62
Average number of employees	6	6	5	6	6

**Simris Group has two outstanding warrant programs.*

INCOME STATEMENT - PARENT COMPANY

SEK thousands	Jul-Sep 2026	Jul-Sep 2025	Jan-Sep 2026	Jan-Sep 2025	Full year 2025
Net revenue	0	0	0	0	0
Other operating income	0	0	0	28	28
Other external expenses	-1 490	-2 035	-4 049	-5 387	-8 285
Personnel expenses	-161	-139	-478	-351	-496
Depreciation and amortization	-573	-746	-2 066	-2 239	-2 986
Operating result / EBIT	**-2 224**	**-2 920**	**-6 593**	**-7 949**	**-11 739**
Financial net	-1 604	-94	-4 833	-882	-3 558
Result before tax	**-3 828**	**-3 014**	**-11 426**	**-8 831**	**-15 297**
Tax	0	0	0	0	0
Result for the period	**-3 828**	**-3 014**	**-11 426**	**-8 831**	**-15 297**

BALANCE SHEET - PARENT COMPANY

SEK thousands	30 Sep 2026	30 Sep 2025	31 Dec 2025
Assets			
Fixed Assets			
Tangible assets	7 895	10 708	9 962
Financial assets	134 886	133 281	130 795
Total Fixed Assets	**142 781**	**143 989**	**140 757**
Current Assets			
Other receivables	5 125	406	13 528
Cash and bank balances	9 890	3 261	1 097
Total Current Assets	**15 015**	**3 667**	**14 625**
Total Assets	**157 796**	**147 656**	**155 382**
Equity and Liabilities			
Equity	54 818	29 370	43 972
Liabilities			
Long-term Liabilities	91 519	89 932	87 680
Short-term Liabilities	11 459	28 354	23 730
Total Liabilities	**102 978**	**118 286**	**111 410**
Total Equity and Liabilities	**157 796**	**147 656**	**155 382**

ABOUT SIMRIS GROUP

Simris Group is a biologics company identifying and commercialising high-value, natural, biologically active compounds found in microalgae and cyanobacteria for extraction and use in biopharmaceuticals, dietary supplements and cosmetics. Simris Group's shares are traded on the Nasdaq First North Growth Market with the short name SIMRIS and ISIN code SE0008091664.

FINANCIAL CALENDAR

Year-end Report 2026	17 February 2027
Annual Report 2025	14 April 2027
Interim Report Q1, 2026	12 May 2027
Annual General Meeting	26 May 2027
Interim Report Q2, 2026	11 August 2027
Interim Report Q3, 2026	10 November 2027
Year-end Report 2026	16 February 2028

Certified Adviser

Amudova AB is the Company's Certified Adviser on Nasdaq First North and can be reached at info@amudova.se or +46 (0) 8-546 017 58.

FOR MORE INFORMATION:

Daniel Kubitza, interim CEO
Phone: +33 6 71 04 21 52
Email: IR@simris.com

KEY FIGURE DEFINITIONS

Balance sheet total - The sum of all assets in the balance sheet or sum of all liabilities and equity.
Equity per share - Adjusted equity (equity and untaxed reserves less deferred tax) divided by the number of shares at the end of the period.
Equity per share after full dilution - Adjusted equity (equity and untaxed reserves less deferred tax) divided by the number shares at the end of the period taking into account after conversion and adjusted for effect of share-based payments.
Cash liquidity - Current assets excluding inventories and work in progress as a percentage of current liabilities
Net revenue - Operating main income, invoiced costs, side income and income corrections.
Earnings per share - Earnings for the period divided by the number of shares after the end of the period.
Earnings per share after full dilution - Earnings for the period divided by number shares after the end of the period, taking into account after conversion and adjusted for effect of share-based payments.
EBIT/ Operating result - Result before financial expenses and tax.
Solidity - Adjusted equity at the end of the period as a percentage of total asset.

This information is information that Simris Group is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 08:00 CEST on 11 November 2026.